These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35853681)

  • 21. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
    Chiang AC; Fernandes AW; Pavilack M; Wu JW; Laliberté F; Duh MS; Chehab N; Subramanian J
    BMC Cancer; 2020 Apr; 20(1):356. PubMed ID: 32345265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
    Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y
    Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338
    [No Abstract]   [Full Text] [Related]  

  • 23. Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.
    Hsu PC; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Wu CE
    Ther Adv Respir Dis; 2022; 16():17534666221132731. PubMed ID: 36305280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
    Sun JM; Park K
    Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.
    Del Re M; Petrini I; Mazzoni F; Valleggi S; Gianfilippo G; Pozzessere D; Chella A; Crucitta S; Rofi E; Restante G; Miccoli M; Garassino MC; Danesi R
    Clin Lung Cancer; 2020 May; 21(3):232-237. PubMed ID: 31735523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
    Mitsuya S; Tsuruoka K; Kanaoka K; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Tamura Y; Imanishi M; Ikeda S; Fujisaka Y; Goto I; Imagawa A
    Anticancer Res; 2021 Oct; 41(10):5137-5145. PubMed ID: 34593465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
    Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
    Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors.
    Menzel M; Kirchner M; Kluck K; Ball M; Beck S; Allgäuer M; Assmann C; Schnorbach J; Volckmar AL; Tay TKY; Goldschmid H; Tan DS; Thomas M; Kazdal D; Budczies J; Stenzinger A; Christopoulos P
    J Pathol Clin Res; 2024 Mar; 10(2):e354. PubMed ID: 38284983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer.
    Bauman JR; Liu G; Preeshagul I; Liu SV; Melosky B; Abrahami D; Li B; Thomaidou D; Duncan K; Krulewicz S; Rupp M; Lin JJ
    Lung Cancer; 2024 Sep; 195():107919. PubMed ID: 39197358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
    Huang YH; Tseng JS; Hsu KH; Chen KC; Su KY; Yu SL; Chen JJW; Yang TY; Chang GC
    Sci Rep; 2021 Jun; 11(1):12084. PubMed ID: 34103652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data.
    Ito K; Murotani K; Kubo A; Kunii E; Taniguchi H; Shindoh J; Asada K; Imaizumi K; Takahashi K; Karayama M; Okuno M; Inui N; Hataji O; Morikawa S; Hayai S; Suda T; Abe T; Tsuda T; Yamagichi T; Kimura T; Oya Y; Yoshida T; Hida T
    Cancer Sci; 2020 Oct; 111(10):3705-3713. PubMed ID: 32639668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world data on efficacy and safety of osimertinib in non-small cell lung cancer patients with EGFR T790M mutation detected by first and repeat rebiopsy.
    Wang Y; Zhang H; Zou Y; Ren X; Wang H; Bai R; Xu K; Xu Y; Zhang Z
    Asia Pac J Clin Oncol; 2023 Dec; 19(6):715-722. PubMed ID: 36756895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
    Hsieh YY; Fang WT; Lo YW; Chen YH; Chien LN
    Int J Cancer; 2020 Aug; 147(4):1107-1116. PubMed ID: 31854456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.
    Kwok WC; Ho JCM; Tam TCC; Ip MSM; Lam DCL
    Thorac Cancer; 2022 Jul; 13(14):2057-2063. PubMed ID: 35668712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs.
    Arrieta O; Hernandez-Martinez JM; Montes-Servín E; Heredia D; Cardona AF; Molina-Romero C; Lara-Mejía L; Diaz-Garcia D; Bahena-Gonzalez A; Mendoza-Oliva DL
    Cancer Biomark; 2021; 32(2):123-135. PubMed ID: 34057135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases.
    Tamura K; Yoshida T; Masuda K; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
    ESMO Open; 2023 Aug; 8(4):101594. PubMed ID: 37517364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Outcomes Beyond 1L
    Mountzios G; Koumarianou A; Linardou H; Boutis A; Mavroudis D; Samantas E; Korantzis I; Athanasiadis E; Fergadis EG; Lampaki S; Georgoulias V; Baka S; Karamouzis MV; Boukovinas I; Andreadis C; Rapti A; Koulouris N; Pentheroudakis G; Froudarakis ME; Somarakis A; Anastasopoulou E; Karadimou A; Papageorgiou F; Paparepa Z; Nikolaou A; Papista C; Syrigos KN
    Anticancer Res; 2023 May; 43(5):2243-2258. PubMed ID: 37097667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study.
    Ng WW; Lin CC; Cheng CY; Jiang JS; Kao SJ; Yeh DY
    PLoS One; 2021; 16(6):e0253335. PubMed ID: 34166400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation Analysis between T790M Status and Clinical Characteristics of Patients with EGFR-sensitive Mutation Advanced NSCLC who Progressed after the First Generation and First-line EGFR-TKIs Administration: A Real-world Exploratory Study.
    Zhen Y; Xu YB; Deng RY; Li M; Ma MT; Zhou ZG; Meng QJ; Gong YN; Zhao LY; Liu YB
    Comb Chem High Throughput Screen; 2024; 27(6):845-853. PubMed ID: 37282652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.